Extract to table

Associate Professor of Hepatology & Oncology at Lakemont Medical Center, has been designated as the Co-Principal Investigator for Site 002, and has agreed to assume the responsibilities and obligations of a Co-Principal Investigator under Protocol PPC-4871-III, applicable regulations, and the Co-Principal Investigator Agreement to be executed concurrently herewith or prior to the effective date of this Individual Site Agreement; and WHEREAS, all capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the MCTA

In the event of a conflict between any provision of this Individual Site Agreement and any provision of the MCTA, the terms of this Individual Site Agreement shall control with respect to site-specific matters pertaining exclusively to Site 002 and the conduct of the trial at Lakemont Medical Center

In all other respects, the MCTA shall govern

1 is true and correct as of the date of execution of this Individual Site Agreement, and Lakemont shall promptly notify Penterra and Veridian in writing of any changes to such information during the term of this Individual Site Agreement

2 — Principal Investigator Designation The Co-Principal Investigator for Site 002 under Protocol PPC-4871-III (CLARION) shall be: Name: Dr

The Co-Principal Investigator Agreement shall set forth the specific duties, responsibilities, and compensation of Dr